Can a Massachusetts resident get peptides by telehealth?
Board of Registration in Medicine Policy 2020-01 (amended October 6, 2022) explains that the Board's regulations at 243 CMR 2.01 define the practice of medicine to include telemedicine, and that the Board reads that definition to cover everything in the telehealth definition at M.G.L. chapter 112, section 5O: the use of synchronous or asynchronous audio, video, electronic media, or other telecommunications technology, including online adaptive interviews, for evaluating, diagnosing, prescribing, and treating. The same policy says no face-to-face encounter is required before care by telemedicine and that the standard of care is the same as in person. The physician must hold a Massachusetts license to treat a patient located in Massachusetts. Board Policy 15-05 (amended June 15, 2023) still requires every prescription, including one issued over the Internet, to rest on a physician-patient relationship, an adequate medical history, and a physical and/or mental status examination. Policy 15-05 quotes a 2002 Federation of State Medical Boards guideline saying treatment based solely on an online questionnaire is not an acceptable standard of care, but the Board does not state that as its own rule. None of the peptides in this database are controlled substances. This record classifies asynchronous prescribing as allowed because the Board policy in force expressly brings asynchronous technology used for prescribing within the practice of medicine and does not require a face-to-face encounter before care by telemedicine. [2] [3] [4] [5]
How does the Massachusetts pharmacy board treat compounding?
| Board | Massachusetts Board of Registration in Pharmacy (Department of Public Health) |
|---|---|
| Eligible substances | Follows the federal 503A framework |
The Board of Registration in Pharmacy licenses pharmacies under M.G.L. chapter 112, sections 24 through 42D, and Board regulations in 247 CMR, including 247 CMR 6.00 (licensure of pharmacies) and 247 CMR 9.00 (professional practice standards, including non-resident pharmacies). Chapter 159 of the Acts of 2014, An Act relative to pharmacy practice in the Commonwealth, passed after the New England Compounding Center meningitis outbreak, inserted sections 39D through 39J into chapter 112: section 39G created a license for retail sterile compounding pharmacies, section 39H a license for retail complex non-sterile compounding pharmacies, section 39I a license for institutional sterile compounding pharmacies, and section 39J non-resident pharmacy licensure. Under section 39J(d), no pharmacy, pharmacist, or outsourcing facility outside Massachusetts may ship, sell, or dispense sterile or complex non-sterile drug preparations into the state unless they were compounded in a facility holding a Massachusetts nonresident sterile compounding license, nonresident complex non-sterile compounding license, or nonresident outsourcing facility registration. 247 CMR 17.00 (sterile compounding) and 247 CMR 18.00 (non-sterile compounding) are posted on the Board's draft regulations page and are not in the Trial Court Law Libraries compilation of current 247 CMR checked on 2026-09-22, so this record treats them as drafts, not adopted rules. Massachusetts has no state bulks list, so peptide eligibility follows the federal 503A framework. [1] [6] [7] [8] [9] [10] [12]
Can you get compounded GLP-1s in Massachusetts?
Because compounded GLP-1s are injectable sterile preparations, an out-of-state telehealth program can ship them into Massachusetts only from a pharmacy that holds a Massachusetts nonresident sterile compounding license, which narrows the pool further. [6] [15]
Prices by channel: semaglutide cost, tirzepatide cost.
Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.
What is the legal access path in Massachusetts?
Access options
Prescriber licensed in Massachusetts, in person or by telehealth
Telehealth prescribing of non-controlled peptides is permitted in Massachusetts. A prescriber may prescribe without a live visit (asynchronous care) when it meets the standard of care.
Check the dispensing pharmacy against the board's license lookup before paying, including out-of-state mail-order pharmacies.
Branded GLP-1 through a retail or manufacturer pharmacy
FDA approved semaglutide and tirzepatide are available by prescription. Compounded GLP-1 limited; see the GLP-1 section for why.
CJC-1295 / Ipamorelin from Bodybuilding Peptides
SponsoredPartner lists from $220/month
Tesamorelin / Ipamorelin from Bodybuilding Peptides
SponsoredPartner lists from $274/month
Semax / Selank from Bodybuilding Peptides
SponsoredPartner lists from $274/month
We may earn a commission from these links.
Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.
Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.
Find a provider in Massachusetts
What you'll actually find in Massachusetts, and how to check
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [19] [20] [21]
No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [22]
What Massachusetts has done
PeptideAgent has not found a board or legislative action on peptides in Massachusetts.
Other states have acted:
- On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [24] Mississippi law
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [25] [26] Louisiana law
Checking the prescriber
Telehealth prescribing of non-controlled peptides is permitted in Massachusetts. A prescriber may prescribe without a live visit (asynchronous care) when it meets the standard of care. [2] [3] [4] [5] The telehealth rule in full.
Checking the pharmacy
Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the Massachusetts Board of Registration in Pharmacy (Department of Public Health); its license search: FDA BeSafeRx: state board of pharmacy license lookups. [23]
If you're going ahead anyway
These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [22]
They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [13] [27] [28]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [23] [29] [30]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [21] [30] [31]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [22] [32] [33] [34] [35] [36]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [22]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [23]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [21]
- Pharmacy: Is this made for me on a prescription written in my name? [31]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [21] [30]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [21]
What is offered for a specific peptide, and what FDA found, is on each peptide page.
Is it legal to buy research peptides in Massachusetts?
M.G.L. chapter 94 (food and drugs) prohibits selling adulterated or misbranded drugs in Massachusetts, and chapter 112 limits dispensing of prescription drugs to licensed pharmacies and practitioners. [6] [11] [16]
Peptide-specific notes for Massachusetts
| Peptide | Note |
|---|---|
| Semaglutide | Available branded from any Massachusetts pharmacy by prescription, including by telemedicine from a Massachusetts-licensed physician. Compounded semaglutide injections are limited to the federal patient specific exception since April 22, 2025, and must come from a Massachusetts sterile compounding licensee. [6] [15] |
| BPC-157 | Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. On October 28, 2026 HHS released a draft enforcement discretion policy covering single-ingredient BPC-157 compounded by a state-licensed pharmacy by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's tested substance, with serious adverse events reported to FDA. It is not an FDA approval, is not binding, and does not cover blends such as Wolverine. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). Massachusetts pharmacies apply the federal test, and an injectable BPC-157 preparation would also have to come from a pharmacy holding a Massachusetts sterile compounding license (M.G.L. chapter 112, section 39G) or, if shipped from out of state, a nonresident sterile compounding license (section 39J). [6] [7] [13] [14] [17] [18] |
Frequently asked questions
Can I get a GLP-1 prescription in Massachusetts through telemedicine?
Yes, from a Massachusetts-licensed physician. The Board of Registration in Medicine treats telemedicine as the practice of medicine under the same standard of care as an in-person visit, and semaglutide and tirzepatide are not controlled substances. [2] [3]
Why are Massachusetts compounding rules stricter than most states?
The 2012 fungal meningitis outbreak traced to the New England Compounding Center in Framingham led to Chapter 159 of the Acts of 2014, which created separate sterile compounding licenses and barred out-of-state compounders from shipping sterile preparations in without a Massachusetts nonresident sterile compounding license. [6] [7] [8]
Can an out-of-state pharmacy ship compounded injectable peptides to me in Massachusetts?
Only if the preparation was made in a pharmacy holding a Massachusetts nonresident sterile compounding license, or in an outsourcing facility with a Massachusetts nonresident registration, under M.G.L. chapter 112, section 39J. Check the Board's license lookup before ordering. [1] [6]
Is compounded semaglutide or tirzepatide still available in Massachusetts?
Only in limited, patient specific cases. The federal shortage allowances ended in 2025, and any compounded injectable must also come from a pharmacy with the right Massachusetts sterile compounding license. [6] [15]
Can a Massachusetts pharmacy compound BPC-157?
Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). State law still applies: Massachusetts has no state bulks list; peptide eligibility follows the federal 503A framework. [12] [13] [14] [17] [18]
Sources
Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.
- [1]Massachusetts Board of Registration in Pharmacy
- [2]Massachusetts Board of Registration in Medicine: physician regulations (243 CMR 2.00), policies, and guidelines
- [3]Massachusetts Board of Registration in Medicine Policy 2020-01, Policy on Telemedicine in the Commonwealth (amended October 6, 2022)
- [4]Massachusetts Board of Registration in Medicine Policy 15-05, Prescribing Practices Policy and Guidelines (amended June 15, 2023)
- [5]M.G.L. chapter 112, section 5O, Telehealth
- [6]M.G.L. chapter 112, section 39J, Non-resident pharmacies; licensure; compounded preparations
- [7]M.G.L. chapter 112, section 39G, Retail sterile compounding pharmacies; licensure
- [8]Chapter 159 of the Acts of 2014, An Act relative to pharmacy practice in the Commonwealth
- [9]247 CMR, Board of Registration in Pharmacy regulations (Trial Court Law Libraries compilation)
- [10]Board of Registration in Pharmacy: draft regulations, including draft 247 CMR 17.00 (sterile compounding) and 18.00 (non-sterile compounding)
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, October 28). Are peptides legal in Massachusetts?. https://peptideagent.ai/legal/massachusetts- HTML link
<a href="https://peptideagent.ai/legal/massachusetts">Are peptides legal in Massachusetts?</a>, PeptideAgent, updated October 28, 2026.